Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Period	YoY Revenue Growth
2021-12-31	16.85%
2022-12-31	-8.84%
2023-12-31	51.99%
2024-12-31	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PVLA	$122.82	+2.32%	0.17M
3
4
5

Palvella Therapeutics Inc. (PVLA) Revenue Growth

Revenue Growth Data

Get Palvella Therapeutics Inc. Data in Excel

More PVLA Financial Data